Immunotherapy | eHealth News | Page 15

Immunotherapy with CD19 chimeric antigen receptor-modified T cells in a defined CD4+/CD8+ ratio can lead to improved disease response and overall and progression-free survival

Remission Up With T Cell Therapy for Non-Hodgkin’s Lymphoma

HealthDay.com - Sep 8, 2016 0

Researchers identify treatment characteristics that correlate with therapeutic response, toxicity

1...13 1415Page 15 of 15

Archives